Show simple item record

dc.contributor.authorWest, Nicholas P
dc.contributor.authorCripps, Allan W
dc.date.accessioned2017-05-03T14:31:24Z
dc.date.available2017-05-03T14:31:24Z
dc.date.issued2013
dc.date.modified2014-05-27T22:25:22Z
dc.identifier.issn2164-5515
dc.identifier.doi10.4161/hv.23254
dc.identifier.urihttp://hdl.handle.net/10072/59229
dc.description.abstractThe European Food Safety Authority (EFSA) has indicated that stimulation of protective antibody titers from vaccination could be used to substantiate a supplement or food health claim on the function of the immune system related to defense against pathogens in healthy individuals. Vaccination allows exposure of the immune system to controlled quantities of antigen and also for assessment of median antibody responses and percentage of responders/non-responders, which provides indication of an integrated immune response to challenge. Probiotic vaccination studies have shown enhanced antibody titers, lower percentages of non-seroconverters and greater percentages reaching minimum cut-off titer values in healthy adults, elderly and children. These results indicate that probiotics are a good candidate to stimulate responses to vaccines and thus, according to EFSA, enhance the function of the immune system related to defense against infection. However, animal research has recently indicated that Foxp3+ T-regulatory cells, recognized suppressors of immune activity, were paradoxically associated with reduced respiratory viral morbidity without compromising viral clearance. These effects conflict with vaccine research findings, which suggest a depletion of Foxp3+ T-regs enhances the immune response. Many probiotics exert anti-inflammatory influence on the immune system and induce T-regs. Given this, caution regarding the applicability of the vaccination model as indicated by EFSA must be exercised. Induction of T-cell immune modulatory pathways may also explain the reduced duration of respiratory illness observed in probiotic clinical studies.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent142712 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherLandes Bioscience
dc.publisher.placeUnited States
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom621
dc.relation.ispartofpageto624
dc.relation.ispartofissue3
dc.relation.ispartofjournalHuman Vaccines & Immunotherapeutics
dc.relation.ispartofvolume9
dc.rights.retentionY
dc.subject.fieldofresearchOther biological sciences not elsewhere classified
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchMedical microbiology
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode319999
dc.subject.fieldofresearchcode3204
dc.subject.fieldofresearchcode3207
dc.subject.fieldofresearchcode3214
dc.titleAre vaccination models suitable to determine whether probiotics have beneficial health effects in the general population?
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Allied Health Sciences
gro.rights.copyright© The Author(s) 2013. This is the author-manuscript version of this paper. It is posted here with permission of the copyright owners for your personal use only. No further distribution permitted. For information about this journal please refer to the journal’s website or contact the authors.
gro.date.issued2013
gro.hasfulltextFull Text
gro.griffith.authorCripps, Allan W.
gro.griffith.authorWest, Nic P.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record